Panitumumab: Casting a Wider Net for Improved Response

Dr. David Kerr reports on a study indicating that widening the search for RAS mutants other than exon 2 can exclude a further 17% of patients with CRC who will not benefit from panitumumab.

Source: Medscape Pathology and Laboratory Medicine Podcast - October 1, 2013 Category: Laboratory Medicine Authors: Medscape Source Type: podcasts